Market capitalization | $30.21m |
Enterprise Value | $-3.05m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.44 |
P/B ratio (TTM) P/B ratio | 0.93 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.76m |
Free Cash Flow (TTM) Free Cash Flow | $-6.89m |
Cash position | $33.28m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast ARCA biopharma, Inc.:
1 Analyst has issued a forecast ARCA biopharma, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.08 -0.08 |
33%
33%
|
|
EBITDA | -8.68 -8.68 |
101%
101%
|
EBIT (Operating Income) EBIT | -8.76 -8.76 |
101%
101%
|
Net Profit | -7.20 -7.20 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
Head office | United States |
CEO | Thomas Keuer |
Employees | 5 |
Founded | 1992 |
Website | www.arcabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.